반응형
| 구분 | 보고서(영문) |
| 제약/바이오/임상시험 (2건) |
Bio/Pharmaceutical Outsourcing Report, June 2024 |
| Emerging Market Outsourcing Report – Q2 2024 | |
| 컨퍼런스/심포지엄/ 학회/기타 (4건) |
EAN 2024 Safinamide Surpasses Rasagiline but Not Opicapone as Add-On Therapy in PD |
| EAN 2024: The Role of B Cells in shaping rituximab use in Generalized Myasthenia Gravis | |
| EAN 2024: Opicapone Demonstrates Efficacy in Real-World Clinical Practice | |
| Tampons Containing Arsenic and Lead Pose Significant Health Risks | |
| 질환별 (9건) |
Frontotemporal Dementia: Competitive Landscape |
| Chondrosarcoma: Competitive Landscape | |
| Osteoporosis: 68-Market Analysis and Sales Forecast | |
| Spinal Muscular Atrophy: Opportunity Assessment and Forecast | |
| Anxiety Identified as Major Indicator of Parkinson’s Disease in Older Adults | |
| First Hepatitis C Self-Test Prequalified by the WHO | |
| Battling Bacterial Behemoths The AMR and MRSA Challenge | |
| Hepatic Encephalopathy: Competitive Landscape | |
| Traffic Air Pollution Increases Dementia Risk |
반응형